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Background: The relevance and quantity of clinical research has caused concern and regulation is claimed to hinder
clinical research. This paper compares clinical research regulations in Finland to those of England, Canada, and the USA
around 2010–2011.
Methods: Several approaches and data sources were used, including semi- or unstructured interviews of experts. For
the analysis, a theoretical framework was made, data from various sources was synthesized, and features of the systems
were simplified and classified. The various specific names and terms used in the data were changed into general ones.
Results: Common structures for the regulation existed in all four countries, but the details and scope varied. The research
regulated within the main system was determined by research type (Finland), the financer of the health system (England),
or research site (Canada, USA). Only Finland had specific legislation on medical research. The overriding impression of the
regulatory systems was one of complexity. All countries had extra regulation for drug research. The types of drug research
covered varied from trials with unlicensed (new) products or new indications (USA and Canada), to all types of
interventional drug research (England), where ‘interventional’ was interpreted broadly (Finland). The complexity of
regulations had led to the creation of various big and small businesses to help researchers and sponsors. There was
notable variation in the role played by the public research funder. The role played by health care was difficult to study
and seemed to involve varying interests as researchers were also health care employees. Research ethics committees
were important and their tasks also included aspects other than ethics.
Conclusions: This study revealed that a comparison between countries can provide useful insights into the distinctive
aspects of each country’s system, as well as identifying common features that require international action.
Keywords: Comparative study, Drug control, Governance, Research regulationBackground
The regulation of clinical research is governed by two
opposing sets of interests. While demand for evidence-
based medicine and the interests of health care and in-
dustry favor research facilitation, the regulators, patient
protection, and autonomy are putting the case for
greater regulation. Concern has been raised about the
relevance and quantity of clinical research and it is even
claimed that regulation hinders research activity [1-4].
Due to the high volume of drug trials, strong commer-
cial interests, tighter control traditionally, and problemsCorrespondence: elina.hemminki@thl.fi
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ective, a special focus has been placed on drug research.
The aim of this paper is to compare clinical research
regulation in Finland to that of three other countries, in
order to illustrate common features and variations
around the period 2010–2011, while focusing on the
various actors involved in research regulation. Research
ethics committees (RECs) will be discussed in more de-
tail in another paper (Hemminki, unpublished manu-
script 2015); only their general structures are presented
here. In all countries compared, particularly England,
changes have occurred since 2011, but in order to pre-
serve a common timeframe these changes are referred
to only briefly. Regulation concerns both research ethicshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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this article, the term research ‘regulation’ is used to
cover both. The focus is on clinical research, defined as
medical research conducted on and with patients. Regu-
lation of medical research using animals, body parts
(samples), or information alone, including the regulation
of registers, records, and bio-banks is not covered; privacy
and data protection issues are not independently considered.
Previous studies have investigated research regulation
in Finland [1,2,5], highlighting various elements in need
of improvement. To better understand the regulation
system and to get ideas for improvements, comparisons
were made with three other countries. The comparison
countries were chosen based on the assumption that
they have a great interest in research regulation, as well
as for reasons of convenience (contacts through which
data collection could be organized). Finland is an EU
country with largely publicly funded health care, con-
ducting much clinical research for its size. England (UK)
is an EU country with a national health care system, a
great deal of clinical research and ongoing discussion of
research regulation. Canada has publicly funded health
care. To some extent, research regulation varies by prov-
ince and our results are mainly based on Ontario, Canada’s
largest province. The USA, a leader in medical research,
has a major international impact on the field.
Methods
Several approaches and data sources were used. The key
method applied consisted of semi-structured and un-
structured interviews of experts. In addition, use was
made of previous reports, documents, presentations in
meetings, observations and, in the case of Finland, previ-
ous knowledge. Empirical data was collected: in Finland
in 2009–2011, in Canada in late 2010, in England in
early 2011, and in the USA in late 2011. Some data was
completed up to spring 2014 using web pages and publi-
cations and, later, interviews.
The data collection conducted in Finland has been re-
ported in more detail in previous publications [1,2,5]. A
total of 26 experts involved in Finland’s research and
health services were purposefully selected to cover the
expertise of clinical research policy makers and regula-
tors. All of the experts approached, or their substitutes,
agreed to be interviewed (15 face-to-face and 11 via tele-
phone) by two researchers with a medical background;
22 chairpersons from 25 official medical RECs were
interviewed by two other researchers, a dentist and a
lawyer.
In the comparison countries, the persons interviewed
were chosen based on previous knowledge of important
institutes in this context, suggestions made by the inter-
viewees, geographical proximity, and availability during
the data collection visits. All persons contacted agreedto participate if the timing was possible. Interviews were
performed by a researcher with a medical background.
In England (London, Oxford), 21 persons were inter-
viewed in spring 2011; in addition, various informal dis-
cussions were held with experts. Feedback interviews
were conducted with four interviewees in late 2013. An
important source of data was the report and background
documents on health research regulation [6]. In Canada
(Toronto), 13 persons were interviewed in the fall of
2010; in addition, informal discussions were held. Six
seminars relating to research regulation were attended
and a meeting of a hospital ethics committee was ob-
served. In the USA (Washington, DC and Baltimore), 24
persons were interviewed and various informal discus-
sions were held in the fall of 2011. Four seminars relat-
ing to the regulation of clinical research were attended.
Informal discussions on the study findings were held
with a few experts in England and the USA in the fall of
2013. In spring 2014, a draft report was shown to two
persons in Canada, England, and the USA, most of
whom had previously been interviewed. The report was
modified in accordance with their comments.
Most interviews were semi-structured, but some were
unstructured and resembled normal discussions. The
themes of the interviews and some pre-prepared ques-
tions were drawn up prior to each interview, but the ac-
tual interview and its focus varied in accordance with
the expert’s position, experience, and emergent informa-
tion. Information and material from previous interviews
were utilized in subsequent interviews. In Finland, the
original questions and themes were chosen by previous
literature and the project researchers’ knowledge and
experience of research regulation; the questions were
reformulated when new information from the inter-
views accumulated. In the comparison countries, the
interviewees were approached with an open mind. Data
collection was a learning process: the questions and
items were first prepared according to the Finnish
experience and background reading, and reformu-
lated by new information in subsequent interviews.
The interviews lasted from 30 minutes to 3 hours.
They were not tape-recorded, but notes were made and
a summary of the interview was drawn up immediately
afterwards. Although a few interviewees were reserved
to begin with, with the exception of two, they soon re-
laxed, a friendly atmosphere prevailed, and the inter-
viewees opened up to share their expertise.
In each country, documents were collected from the
web pages of the institutions involved, or were handed
over during the interviews. The relevant publications
were sought from literature databases and from refer-
ences given during the interviews.
The analysis was material based (grounded theory).
During data collection, preliminary classes of regulation
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lection, tables, organized by regulation dimension each
containing many items, were created. The tables were
preliminarily filled, as recalled from the data collection.
Then, country-specific interview notes and documents
were iteratively read by one researcher; notes were made
on various topics and dimensions using self-adhesive
notes, and organized by topic/dimension and by country.
The framework was modified and made more detailed
during note making. Data from various sources was
synthesized and the features of the systems were simpli-
fied and classified. If an item was not found in the ori-
ginal country-specific notes, documents and web-pages
were searched for if the item was an unequivocal fact.Permissions and ethics
A positive statement was issued by the THL (National
Institute for Health and Welfare) ethics committee on
the project as a whole (MERGO ethical review and
administrative governance of clinical research) (June
17, 2010, amendment Jan 27, 2011). All interviews
were voluntary; the interviewees understood the pur-
pose of the interviews and were interviewed as ex-
perts. In Finland, the main project was explained and
the purpose of the interview (to obtain an expert
view) was stated. In the comparison countries, the
main project was described only superficially, but the
purpose of the visit and the interview (to obtain com-
parative data and gain a better understanding of the
principles of research regulation) was explained. Per-
sonal views and experiences were requested as well
as facts. The interviewees were reassured that theirTable 1 Context of clinical research regulation in Finland, com
around 2010
Finland Engla
Population size (millions) 5.4 56
Health services Mainly publicly funded
and organized
Public
organ
Local drug industry and exports 0 +++
Local drug industry research + +++
Clinical research activity ++ +++
Number of drug trials
(relative to population size)
++ ++
Government promotion of clinical
research
0 +++
Government promotion of commercial
clinical research
0 +
Research within same regulations Medical research narrowly Medic
broad
Specific laws on drug trials Yes + EU directive Yes +
0/+ provides a subjective estimate of the importance of the issue, relative within th
EU, European Union.names would be kept confidential. The documents
used were public.Terms used
Different terms, varying between the interviewees and
documents, were used in each country. Specific names
and terms were transformed into general ones, of which
the key terms are: clinical research, research conducted
on and with patients; clinical trial, research that evalu-
ates interventions using experimental methods (not
restricted to drugs); health ministry, the ministry/de-
partment/government office which deals with health
issues (usually in addition to other matters), with the
name and organizational structure varying by country;
research ethics include human subject protection,
conflicts of interest, and research integrity (avoidance
of data falsification, etc.); RECs, known as research
ethics boards in Canada and institutional review
boards in the USA; ‘regulation’ covers laws, rules,
overseeing, and governance.
Results
Context
Finland is a Nordic state in the EU, with a population of
around 5 million (Table 1). Its health services have two
dominant systems: a municipality-based, tax-funded,
area-based system covering most in-patient care and
much outpatient care, and a national health insurance
scheme subsidizing part of private care, occupational
care, drugs, travel, and the costs of sickness absence
from work. England is an EU country with a national
health service – an area-based, tax-funded, government-pared to England, Canada (Ontario), and the USA
nd Canada USA
13 312
ly funded and
ized
Publicly funded, privately
organized
Mainly privately funded
and organized
+ +++
+ +++
++ +++
++ ++
+ +
++ ++
al research
ly
Broad (human research) Broad (human research)
EU directive Yes Yes
e four countries; 0, no or little activity.
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were administered and financed by trusts. The system
has recently undergone various changes.
In Canada, health care providers were privately orga-
nized but publicly funded via a detailed billing system.
Health care facilities were owned by non-profit corpora-
tions. Units and practitioners billing the government
were not allowed to run a private practice, making private
practice marginal. The USA had a patchwork of different
systems. Health care was largely privately organized and
private insurance systems played an important role. How-
ever, private services obtained a notable part of their in-
come from tax-paid insurance (Medicare and Medicaid)
and there were also large federal and state-organized ser-
vices. Most health care providers worked without a defined
population base, although there were also large pre-
payment systems.
In Finland and Canada, the local drug industry and its
role in research were small (Table 1), but many small
bio-technology companies and other health technology
firms operated. In England and the USA, the drug industry
was strong, with many large multinational companies.
There were also many health technology firms of other
kinds.
All four countries had a strong tradition of clinical re-
search (Table 1). The number of drug trials (in relation
to the population) was high in all four countries. Practically
all clinical research was carried out through health services,
but some research institutes also performed clinical
research. Phase I drug trials (done among healthy
volunteers) sometimes occurred in special research
centers.Government facilitation of clinical research
In Finland, the health ministry distributed state subsidies
for university level research on public health services,
but they have been notably declining in size (Table 1).
The subsidies were paid to municipalities as compensa-
tion for research costs and were not regarded as facilitat-
ing clinical research as such. In England, the National
Health Service (NHS) had actively facilitated clinical re-
search using various methods, including support via the
National Institute of Health Research (NIHR). The
NIHR had been an important actor through its infra-
structure, funding, and clinical research networks. In
Canada, various government task forces and programs
had aimed to facilitate health research, but not as sys-
tematically as in England. In the USA, the government
was using various funding mechanisms for health re-
search, including the National Institutes of Health (NIH)
intramural and extramural funding, the Agency for
Healthcare Research and Quality, the Patient-Centered
Outcomes Research Institute, and other federal agencies.With the exception of Finland, governments had also
actively promoted commercial clinical research (Table 1).
The interviews and documents consistently showed that
drug trial operations (and other research on health tech-
nology products) departing to lower-cost, less-regulated
countries, was a driving force behind government ac-
tions. Depending on the government structure, the
relative role of ministries (health, research/innovation,
finance, and industry/trade) varied, as did the mecha-
nisms of promotion.
Scope of research within same regulations
Only Finland had detailed legislation on medical re-
search; the USA had an enabling research law (National
Research Act) (Table 1). Canada and England did not
have a specific law on research or medical research, but
semi-legal circulars and standing orders were issued by
their health ministries. Various laws dealing with specific
types of research or populations were present in all four
countries. All countries had enacted a law on clinical
drug trials, which varied in scope (Table 1).
In Finland, the law provided a narrow definition of
medical research and other health research, and other
human research had voluntary regulations. In England,
there were separate regulations governing medical and
other human research, but the definition of medical
research was broad. In Canada and the USA, regulation of
medical and clinical research was part of human research
regulation, covering all research involving humans or body
parts. With the exception of Finland, the rules varied
based on where the research was being performed or who
was funding it (see the section on RECs).
National leadership
In Finland, clinical research was not the identified re-
sponsibility of any ministry; the tasks were mainly di-
vided between the health and education ministries
(Table 2). The medical research law was initiated and
sub-laws issued by health ministry, but the ministry was
not actively involved in clinical research. The education
ministry was responsible for academic research in gen-
eral. Regulatory tasks were divided up, with ethics com-
mittees (under health services) and a drug regulatory
agency (under the health ministry) being the strongest
actors.
In England, the health ministry (via the NHS) had a
strong position. Several bodies within the NHS were
involved in regulating clinical research. The Health
Research Authority (HRA), established at the end of
2011, had started to play an important role. The drug
and device control agency (Medicines and Healthcare
Products Regulatory Agency; MHRA) regulated clinical
research using drugs and medical devices. In Canada, the
health ministry was the responsible ministry, acting
Table 2 Actors in the regulation of clinical research in Finland, compared to England, Canada (Ontario), and USA,
around 2010
Finland England Canada USA
Responsible ministry Two (health and education) Health Health Health
National leadership None NHS a, MHRA CIHR OHRP and FDA
Government research
funders
0 + +++ +++
Health care + ++ ++ +++?
Permission giver “Head physician”/Health care
unit b
NHS Trust “Head physician”/Health care
unit b
“Head physician”/Health care
unit b
Procedures for permission Light Bureaucratic Effective/professional Effective/professional
Conflict of interest bodies No Integrated to
RECs
Yes + Yes +++
Researchers’ impact + +++ + +++
Regulation business 0 NK ++ +++
Drug research particularly
Drug control agency c ++ ++ + +++
Drug agency costs Mainly fees Mainly fees Taxation and fees (~50%) Taxation and fees (~50%)
Products covered Drugs Drugs (devices) New c drugs + devices New c drugs + devices + food
0/+ gives a subjective estimate of the importance of the actor, in relative terms within the four countries; 0, no or little activity. CIHR, Canadian Institutes of Health
Research (a research funder); FDA, Food and Drugs Administration; NHS, National Health Service; MHRA, Medicines and Healthcare Products Regulatory Agency;
NK, Not known to me; OHRP, Office of Human Research Protection.
a Since 2012, the Health Research Authority has played a central role.
b This task was delegated to someone among the health care providers, e.g., a clinic head.
c For new drug trials.
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tutes of Health Research (CIHR). However, the CIHR was
a component of the Tri-Council funding agency, working
under the same rules as other government research fun-
ders which were under other ministers. In the USA, the
health ministry (Department of Health and Human Ser-
vices, DHHS) was the leading ministry in clinical research
regulation. Its office of research regulation (Office of Hu-
man Research Protection; OHRP) played a coordinating
role in regard to other departments and agencies, and
interpreted federal research regulation (Common Rule).
Another DHHS agency, the Food and Drug Administration
(FDA), regulated trials on new drugs and devices; FDA
functions had had spill-over effects on other types of
clinical research and other regulators using drug re-
search rules for other type of research.
Government research funders
In Finland, government research funders, including the
Academy of Finland, TEKES (Finnish Funding Agency
for Technology and Innovation), and the health ministry
(subsidies for health services), had not been important
in regulating clinical research (Table 2). In England, both
the Medical Research Council and private research fun-
ders had issued guidance on clinical research. However,
they had played a more modest role than the NHS. In
Canada, guidelines by the main government funders –
including the CIHR – on ethics and related proceduresformed the cornerstone of clinical research regulation.
These guidelines, the Tri-council policy statement, cov-
ered all types of research involving humans. They were
enforced by requiring that all research conducted within
an institute abide by them, the institute to be eligible for
any funds from the CIHR or other government funders.
In the USA, to be eligible for federal funding, either for
research or health care, an institute had to follow the
rules issued by the relevant ministry (DHHS). Further-
more, the NIH had issued extensive regulations covering
intramural research, with spill-over effects on extramural
funding.
Health care organizers and providers
In all four countries, permissions for clinical research
projects were granted by a nominated person at the sites
at which patients were recruited or data collected; if ex-
ternal funding was being used, contracts were also usu-
ally made (Table 2). Health care units also hosted RECs.
Institutions, rather than individual researchers, bore the
relevant legal and financial responsibility, for which rea-
son various mechanisms had been created to avoid eth-
ical and legal problems in research. In the USA and
England in particular, it was reported that real and al-
leged scandals had raised health care providers’ interest
in this.
On the other hand, university level institutes wanted
to promote research; there was concern that commercial
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hospitals to more attractive sites (smaller hospitals, pri-
mary care, private research companies) and countries. In
all four countries, institutional structures were in place
within university attached health care units, in support
of researchers. In England, NHS trust offices facilitated
clinical research by providing infrastructure for NHS-
supported non-commercial research. In Finland and
Canada, regulation and research facilitation were often
intermingled at personal level, same persons being
responsible both for research facilitation and control.
Particularly in the USA, in university affiliated units,
research was important to improving services as well
as to patient and physician recruitment.
In Finland, the granting of permission for research was
usually straightforward, but the paperwork could be
tedious. Ethics committees also carried out administrative
work and checked that laws were being followed. In
England, permission to do research was granted by the
care organizers, the NHS trusts. The official granting
permission could be an administrator with no direct
interest in having research done within the unit.
Permission-seeking was not streamlined and criticism
was directed at the slowness and complexity of the
process. Some trusts would review the ethics and scientific
value of a project and might implement their own
requirements.
In Canada, the processes involved in obtaining re-
search permission and making contracts were well orga-
nized, focusing on practical issues. The regulation
structure could be divided into specific units, such as
contracts and money, ethics committees, and conflicts of
interest. Research was mainly administered by research
institutes and administratively separated from patient
care and hospitals. Due to the complexity of the system
in the USA, a full picture of the interests of health care
organizers and providers was not obtained. However,
RECs also seemed to play a key role with regard to
permissions, contracts, and other practical issues, even
though these were administratively separate.
Conflicts of interests (COI)
COI regulation was mainly understood to involve financial
issues. In Finland, there were no separate bodies for
checking COI, a vague duty of RECs (Table 2). No trans-
parency among research participants was required, and no
structures existed for overseeing competition or other
conflicts of interest between the permission-giver and the
researcher. In England, RECs were given the task of
checking researchers’ COIs and National Research Ethics
Service (NRES) advised that research participants should
be informed about COI. In Canada and the USA, specific
bodies or designated persons were assigned to check on
COI issues. In Canada, checking was performed by localresearch offices, but the transfer of such duties to special
boards was under planning. In most cases in the USA,
special offices or nominated boards reviewed COI issues
and disclosers.
Academic actors
Scientific journals and associations, researchers, univer-
sities, and other scientific bodies had had a major impact
on clinical research regulation by creating rules and
practices, through education and self-regulation, and
through researchers becoming research administrators.
Data on academic actors were not systematically col-
lected, but some observations from interviews and docu-
ments are given below. In all four countries, academic
clinical researchers stated that they were unhappy with
at least some aspects of research regulation. In most
cases, the researchers had made no personal protests on
this basis, since this may have harmed their (future) re-
search projects. In Finland, clinical researchers were or-
ganized into various associations with no common voice.
Unlike the drug industry, for example, they were not col-
lectively consulted on research regulation.
In England, on the initiative of researchers, the health
ministry had asked the Academy of Medical Sciences,
which represents research oriented physicians, to review
the system of medical research regulation [6]. This had
contributed to the reorganization of NHS research regu-
lation and the creation of the HRA. In the EU, some
clinical associations, such as the European Association
for Cancer Research, had actively lobbied for the im-
provement of EU clinical trials regulation. In the USA, a
group of concerned researchers was behind the initiative
to change the leading document on human research
regulation (Common Rule). The Institute of Medicine
had held seminars and published books on hindrances
to medical research and the actions needed, with a focus
on drug research.
Regulation businesses
Regulatory requirements had led to the creation of vari-
ous kinds of businesses to help researchers and research
sponsors fulfill the requirements, particularly in the USA
and Canada. This was less common, or at least less visible,
in Finland and England. These businesses included private
RECs and contract research organizations (covering the
full package of regulations or specializing in certain as-
pects only, such as monitoring, contracts, or ethics educa-
tion) and firms accrediting human research protection
programs and RECs.
In the USA, public institutes and professional associations
had also created programs around medical research regula-
tion, including legal and ethical education, and trial registra-
tion. Institutions, such as the NIH, and large universities
and affiliated hospitals had constructed infrastructure and
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cialists, and patient recruitment offices. Professional ethics
and regulation associations, trade unions of sorts, had been
established, such as the Public Responsibility in Medicine
and Research for regulators and REC members in the USA,
which was running a program certifying REC members.
Ethics had been professionalized to a large degree.
Drug control agencies
In all four countries, (some) clinical research involving
drugs were governed by additional laws and require-
ments, and had separate drug control agencies. Such
agencies covered drugs only (Finland), drugs and devices
(England, Canada), or drugs, devices, and food (USA). In
Finland and England, the agencies were financially
dependent on their tasks, with various permission fees,
particularly drug licensing fees, making up most of their
income. In England, clinical trial review fees were esti-
mated to account for around 4% of the agencies’ income.
In the USA and Canada, no specific charges were in-
voiced for trial evaluations, since these were rolled into
licensing fees covering around half of the agency’s costs
(Table 2). The EU’s clinical trials directive (Directive on
Clinical Trials on Medicinal Products in Human Sub-
jects, CTD, 2001/20/EC) was a supranational law regu-
lating drug research in Finland and England. It had been
criticized in various respects; it was claimed that it had
discouraged non-commercial research and made re-
search costly and bureaucratic.
The types of drug research covered varied (Table 2). In
Canada and the USA, only trials with unlicensed (new)
drugs or those on new indications (or administration in-
creasing risks) were covered. The EU’s clinical trials
directive stipulated coverage of all ‘interventional’ drug
research. In Finland, the Finnish Medicines Agency
(FIMEA) interpreted the directive as even applying to
some surveys and other non-experimental drug re-
search. However, the FIMEA had simpler procedures
for research on licensed drugs and waivers of fees in
cases of non-commercial researchers. In England, the
MHRA had worked to narrow the interpretation of the
EU directive in regard to licensed drugs and suggested
a proportionate review, i.e., tailored to fit the expected
risk.
The clinical trials directive had had an impact on clin-
ical research regulation over and above drug trials. In
Finland, the directive was integrated into the medical re-
search law, influencing the principles governing other
types of medical research. In England, the directive re-
quirement for one-committee handling of multi-center
studies had also led to one-committee handling in other
medical research.
Because the agencies reviewed drug research inde-
pendently of RECs and research permission givers, drugtrials were reviewed twice (or three times). In Finland,
the review focus in the drug agency was on legal and
safety aspects, reflecting the main tasks of the drug
agency (licensing medicines for sales, inspecting pro-
ducers and sellers, and overseeing marketing). Physical
inspections of trial sites were rare. A problem was the
lack of scientific resources for reviewing novel research.
In England, trial site inspections played a larger role
than in Finland. The way in which the inspections were
performed was criticized as often intimidating researchers.
In the USA, the drug control agency (FDA) had trad-
itionally played a strong role in overseeing drug trials.
Trial reviews were integrated into licensing procedures,
and the same persons performed both reviews. Review
was thorough, and selective onsite inspections of actors
involved in drug trials – including researchers and RECs –
were important. The law was highly specific with regard
to trial contents and the FDA had been proactive in set-
ting standards. However, advice and regulation were con-
cerned only with research for drug licensing. The agency
advised researchers or their sponsors on how the agency
thought a trial should be performed to make it useful for
licensing. An educational approach of this kind seemed
acceptable to the drug companies, but not always to estab-
lished academic researchers. In Canada, according to in-
terviewees, the drug control agency (Health Canada)
played only a modest role in drug trial regulation. The
agency inspected a small sample of the trials underway.
Research ethics committees (RECs)
In all countries, RECs were key actors in regulating clin-
ical research (Table 3). Their functions involved more
than just evaluating the ‘ethics’ (human subject protec-
tion) of individual projects. Their main structural fea-
tures are described here and a more detailed description
of their work will be given in another paper (Hemminki,
unpublished manuscript 2015).
In Finland, the medical research law required RECs to
deal with ‘medical research’, and the law and its sub-laws
were detailed in RECs mandate and tasks. In England,
RECs for NHS-based research were specified in regula-
tions issued by the health ministry. RECs did not consti-
tute legal bodies in general, but functioned as such
under separate laws, regardless of the location of the re-
search, in regard to specific patient-groups (such as
mentally handicapped persons) and interventions includ-
ing drugs. In Canada, RECs had been formalized under
the requirements of the main public funder. In the USA,
the national research act stipulated that human research
had to be approved by a REC. More detailed require-
ments were stipulated under federal government regula-
tions (Common Rule).
In Finland, RECs were area-based and had a monopoly:
they handled all medical research (as defined by law) in
Table 3 Research ethics committees (RECs) in clinical research regulation a in Finland, compared to England, Canada
(Ontario), and USA, around 2010
Finland England Canada USA
Importance +++ ++ +++ +++
Main basis Research law; EU Health ministry + NHS
regulation; EU
Requirement from research
funder CIHR
Research law; health ministry
regulation
Area responsibility Yes No, inclusive No, selective No
Number Few, law defined Declining, NRES defined Many, free Many, free
Private RECs No Few Yes Yes, important
All clinical research in the main
system
Yes Not research outside NHS Not research outside health
care units
Yes
Appointing body Hospital district NRES Hospital board b Hospital b/private
Funding Fees + hospital
district
NHS Fees + hospital b/grants Hospital b/fees (private)
REC control body No Yes, strong NRES No Yes, OHRP + FDA
0/+ provides a subjective estimate of the importance of the issue, on relative terms within the four countries; 0, no or little activity. CIHR, Canadian Institutes of
Health Research; EU, EU Clinical trials directive; FDA, Food and Drug Administration; NRES, National Research Ethics Service; NHS, National Health Service; OHRP,
Office of Human Research Protection.
a Within the main health care system; two systems in the USA.
b Hospital or other health care unit.
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vestigator) (Table 3). In England, researchers could choose
an NHS REC, which then had to consider the proposal. In
Canada, RECs were health facility (hospital) based, sub-
stance based, or private. If the place from which the pa-
tients came had a REC, researchers were supposed to use
it. RECs could choose which applications they handled. In
the USA, the situation was the same as in Canada, but pri-
vate committees played a bigger role.
In Finland, only a small and regulated number of RECs
dealt with clinical research (21 (5 since 2010) and a cen-
tral committee) (Table 3). In England, since 2004, the
number of RECs had been regulated by the REC control
body and had declined from around 200 in 2002 to
around 80 in 2010 (69 in 2013). In Canada, RECs could
be freely established and were numerous, and practically
all university-affiliated hospitals had their own. Likewise,
the USA had a large number of RECs (around 4,500),
and several RECs could be located within one institute
or hospital.
In Finland, there were no private RECs (Table 3). In
England, only 5 private RECs remained by 2010, which
mainly handled applications for Phase I drug trials.
Private RECs were regulated by a government body
(Appointing Authority for Phase I Ethics Committees)
and funded by handling fees and a health ministry
grant. These committees were amalgamated with the
NHS system by 2013. In Canada, private RECs were
used by commercial firms, particularly for Phase I drug
trials on special testing sites, and by small hospitals/
health facilities which did not have their own RECs.
Private RECs could not be used if the research site was
a receipt of government research funding. PrivateRECs were unregulated and attempts to create an ac-
creditation system had not succeeded by 2010.
In the USA, private RECs played a major role.
Their numbers were small (around 30), but they were
large. They were much used by drug firms and other
private companies, but also by large medical insti-
tutes. Most new drug trials were evaluated by private
RECs. Large private RECs also had research-related
activities other than ethics reviews. Large private
RECs were accredited and, like other RECs, overseen
by the REC control body. The drug agency (the FDA)
inspected private RECs, which evaluated new drug or
device trials. It could demand corrective measures or
sanction RECs.
Interviewees’ opinions of private RECs varied not-
ably. The potential problem of giving a positive state-
ment due to incentives was obvious and ‘buying
reviews’ was heavily criticized by some. Private RECs
also paid their experts for reviews performed. On the
other hand, private REC’s were liked by commercial
sponsors and the FDA, possibly due to the speed and
technical quality of their work. Furthermore, some
claimed that private RECs were more independent
than institutional ones, which may take account of in-
stitutional interests, and in various documents the
word ‘independent’ rather than ‘private’ was used.
All four countries had RECs other than those de-
scribed above, which handled health research beyond
the mandate of the main REC system (Table 3). These
were institutionally based and did not usually handle
clinical research. In England, clinical research per-
formed outside the NHS, for example abroad, could
be handled by research institute RECs.
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districts (formally only since 2010) (Table 3). In England,
since its creation in 2000 the REC control body had
appointed and advertised local REC members; before
then, RECs had been appointed by NHS trusts. In
Canada, institutional RECs were appointed by hospital/
health facility boards. In the USA, appointment proce-
dures varied by institution, but usually involved a person
responsible for human research protection matters; federal
government regulations required such a person in each
institute. Private RECs in Canada and the USA nomi-
nated their own members.
In Finland, REC costs were covered by fees and public
money, often from a special state subsidy intended to re-
imburse research costs in hospital districts. A handling
fee was regulated by a sub-law and non-commercial re-
searchers could apply for an exemption. In England,
costs were fully covered by the NHS. In Canada, RECs
charged industry but not academic researchers. Money
came from the general funds of hospitals/health facilities
or grant overheads. Likewise, in the USA, the costs were
usually covered by institutions.
In England and the USA, RECs were regulated and
supported by a public body (subsequently known as the
REC control body) (Table 3). In Canada, there had been
an educational body, the National Council on Ethics in
Human Research, but its government funding was cut in
2010. In England, the REC control body (originally the
Central office for RECs, and later the NRES) controlled
local RECs, appointing, crediting and auditing them.
The secretariats of RECs were NRES employees. NRES
has been pro-active in its work, having reduced the
number of RECs, streamlined and created common pro-
cedures, and introduced a central electronic submission
system for applications. The NRES did not review appli-
cations and, in the case of a complaint, referred the
application to another local committee for a second
review.
In the USA, the OHRP registered RECs in response to
applications and issued assurances of compliance with
federal regulations. Researchers could complain to the
OHRP, which could organize a re-review. The OHRP
hosted a national committee (the Secretary’s Advisory
Committee on Human Research Protections), which
provided expert advice and recommendations to the
health ministry on ethics and research regulation.
In Finland, the central committee (National Committee
on Medical Research Ethics (TUKIJA)), appointed by the
health ministry, had a dual function. It was the primary
address for applications for multi-center drug trials (and
for all drug trials since 2010). Secondly, it provided guid-
ance and education to local RECs, giving second opinions
in the case of complaints. However, the committee had no
formal power over local RECs. Although the committeecould delegate the handling of drug trial applications to
local RECs, and most had been delegated, the emphasis
was still on drug trial reviews and the committee’s other
activities were modest. The central committee earned
most of its income from handling fees.Discussion
Few previous studies have analytically compared re-
search regulation between different countries. A study
by Veerus et al. [7] compared the legislation on medical
research and structural features between RECs in all EU
countries. Two working reports have described differ-
ences and similarities in the regulation of drug trials in
EU countries; one included England and Finland [8],
while the other included England alone [9]. The study by
Veerus et al. [7] was based on a synthesis of documents,
while the two working reports were based on reports by
country representatives, which varied from one country
to another [8,9]. The facts available from the two reports
of the two EU countries agree with the findings of this
study. Veerus et al. [7] identified notable variation based
on the type of medical research regulated by law, and on
the numbers and working principles of RECs.
The overriding impression was that of a highly com-
plex research regulation system, partly varying between
different types of research and involving a range of actors.
This agrees with previous conclusions based on evidence
from England and the USA [6,10,11]. Protection of patient
safety was the main aim of regulation, but many other in-
terests were also involved, including the protection of eco-
nomic, institutional, and professional interests. The aim of
clinical research is to improve patient care, and the facili-
tation and regulation of clinical research should respond
to that [1-3]. The current regulatory complexity appeared
to be largely irrational, probably arising from piecemeal
reactions to specific problems and scandals in the past.
Thus, the new English HRA is of great interest in terms of
future developments. If successful, it may have an impact
outside England.
Various structures for regulating clinical research
existed in all four study countries. Most structures could
be found in all countries, but differed in their detail and
scope, regardless of the international nature of biomed-
ical ethics rules, medical research and health care con-
tent. Some such variation may be due to the government
structure, as well as its organizing and financing of
health care and medical research. Membership of the EU
had an impact due to the influential clinical trials direct-
ive. Lacking data on the experiences of researchers and
research subjects, it cannot be reliably judged which of
the study countries had the best regulation system.
However, if asked for a view, the English model could be
examined for further ideas on reasonable research
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regulation in particular.
An important feature lay in the kind of research regulated
within one (the main) system, i.e., whether this depended
on the research type (Finland), the party funding the health
system (England), or the research site (Canada, USA). In
Finland, a clear distinction was made between medical and
other human research. However, such a distinction was
problematic, both theoretically and in practice, particularly
given that medical research regulation was law-based while
regulation of other research was voluntary.
Only Finland had specific and detailed legislation on
medical research. However, all countries had a large
number of legal and semi-legal rules regulating research
and covering specific aspects of clinical research. Laws
are a cumbersome tool for regulating research details,
since legislation cannot account for all situations and
exceptions. In this respect, the US’s approach of enacting
a general research law to set principles, and regulating the
details on the basis of rules which can be changed more
easily, was better. The content of the detailed law in
Finland may have contributed to clinical research regula-
tion focusing on legality, patient safety, and scientific qual-
ity. Other aspects relating to good science (conflicts of
interests, transparency, availability of results, etc.) were
poorly developed.
The existence of various financial interests and pres-
sures, including those of health service payers, may be a
reason for the lack of a rational and simple regulatory
framework for research. Research regulation is not a
technical issue, but deals with power and money. It is a
tool for determining whose view on medicine and health
care will be followed. Much clinical research is related to
the marketing of health care products. For drug firms,
drug trials form part of the marketing chain [12]: drug
trials are performed in order to obtain data for a marketing
license, to tie experts and institutions into a product or
firm, and to market the product before the sales license is
granted. The complexity of research regulation had led to
the formation of various large and small businesses with
the aim of assisting researchers and sponsors [13] within
contract research organizations [14]. The research busi-
ness is likely to oppose simplifying and rationalizing the
regulation system, since its livelihood depends on the sys-
tem’s complexity. Conflicts of interest were an important
regulation topic in Canada and the USA, but not in the
two European countries studied.
Data on the costs of regulation systems was not available.
However, the sheer volume of actors and of the require-
ments imposed on researchers suggests that the costs are
high. Furthermore, the intimidating atmosphere created by
some research regulation may have resulted in the assump-
tion that certain activities are mandatory, even though this
is not the case, e.g., in drug trial monitoring. Research costshave a direct impact on the volume of and approaches
taken to research. In the long term, such costs are imbed-
ded in the costs of health care. Previous studies on regula-
tion costs as a whole were not found, but studies from the
USA have estimated that the costs of one section of regula-
tion, that imposed by RECs, were notable [15,16].
Clinical research with drugs was more extensively reg-
ulated than other clinical research, involving additional
structures and specific regulatory bodies and laws. In all
countries, the main tasks of the drug control authority
(drug licensing and overseeing drug producers, sellers,
and marketing) differed from those of the research
world, which led to discrepancies. Extra regulation relat-
ing to drug trials may be due to history (visibility of drug
related harms), the large volume of drug trials, and the
strong financial power of the drug industry and its cen-
tral role in drug research. Tighter control on drugs may
be appropriate in the case of new products intended for
routine clinical use. Legislation in the USA and Canada,
restricting the mandate of drug control authority on re-
search aimed at obtaining a marketing license, was bet-
ter than that in Finland and England, in which a variety
of poorly defined types of drug research were put under
the same regulation. The main cause for this was the
highly detailed EU Clinical trials directive, which covered
all interventional drug research and the broad national
interpretation of the term ‘interventional’. The various
problems associated with the directive, and its failure to
achieve the aims set for it, have been much discussed
[1,8,17]. In 2014, the directive was revised to alleviate
these problems, but it remains to be seen how the new
law will change regulation in practice. However, there
has been no change in the basic notion that drug re-
search should have a more extensive and different set of
regulations than other clinical research.
The role of health care proved difficult to define.
Health care seemed to have various roles mixed with
those of researchers, who were health care employees. In
the USA and Canada, research regulation was related to
the level of liability of health care units, which tended to
make them avoid risk. Since clinical research has a direct
impact on patient care, one might assume that health
care has a strong interest in facilitating and directing
clinical research. This was the case in England, but not
in Finland; the data did not allow conclusions to be
drawn about Canada or the USA with its highly varied
health care system. In the USA, a topical issue was the
integration of clinical trials and care [2]. The general un-
derstanding of what constitutes research and what re-
quires informed consent seemed to be changing.
RECs were important to regulation in all four coun-
tries and their tasks included aspects other than ethics
(Hemminki, unpublished manuscript 2014). Although
RECs had similar core tasks, there were notable variations
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sions on the need to improve them. In England, REC ac-
tivity had been transformed into a clear, and apparently
well accepted, system. In Canada and the USA, RECs
formed part of institutions (hospitals), which had the
benefit of allowing closer integration of research with pa-
tient care. However, institutional conflicts of interest and
institutional liability problems existed. Furthermore, it is
likely that the large number of RECs led to variation and
difficulties in multi-site research.
Strengths and weaknesses
Most data from the four countries was collected by one
person. Use of a single data collector was a strength
which enabled the examination of each system from the
outside on a similar basis. When local experts are asked
to describe their own system, they commonly fail to ob-
serve the system’s particular features. Secondly, use of a
single interviewer enabled information from one inter-
view to be used in the next.
Weaknesses included the difficulties inherent in any
country comparison, the limited amount of data col-
lected on complex issues which were difficult to define,
and the failure to define all aspects relevant to clinical
research regulation equally well. As a result, the findings
presented are simplifications. Only the main features
were described, not the many exceptions and nuances.
RECs were given the deepest coverage, since they were
important actors and relatively comparable between
countries; the content details will be reported elsewhere
(Hemminki, unpublished manuscript 2015). No previous
studies comparing all research regulation structures
existed before the study, and several relevant aspects
were only identified during data collection. As the inter-
views were aimed to gather basic descriptive information
as well as the viewpoints of the informants, the aspects
covered varied between interviews.
Inherent difficulties in country comparisons include
those resulting from varying health care systems and
roles played by government/public actors, and the fact
that some tasks were handled by different actors in dif-
ferent countries. RECs and drug trial authorities were
most comparable. Some of these structural differences
became apparent only during the interviews. Due to lim-
ited resources, there was no way of approaching infor-
mants for a second time to enquire about items which
had arisen after their interviews. A further difficulty was
that, during the study, a great deal occurred in clinical
research facilitation and regulation. Furthermore, the
interviewed persons were usually aware of planned changes,
which may have influenced their views accordingly.
Data confidentiality, data access, secrecy, and privacy
issues were not systematically studied, even though they
are topical to research regulation. Such issues are highlydependent on the general legislative framework and culture
of each country, on which sufficient comparative data was
lacking.Conclusions
This study demonstrated that a comparison between
different countries can provide useful insights on the
system within each country, as well as revealing com-
mon features which may require international action.
In most cases, country specific differences probably do
not correspond to actual differences in the need for re-
search regulation. Differences in structure also suggest
that the processes and end results can vary. My impres-
sion was that, while regulation was extensive, it is not
necessarily focused on the correct issues. The complex-
ity of the system suggests that useful research is not en-
couraged but may be hindered.
Certain features of research regulation in individual
countries could serve as a model for other countries: the
streamlining of the ethics committee system in England,
the content advice provided on the handling of ethical
issues in Canada, and the separation of drug trials to be
used in licensing and other drug research in the USA
are examples. Finland could learn a great deal from the
other countries and an article has been written on im-
proving the local control system [5].
Further country comparisons, with greater in-depth
analysis of the key aspects, would be useful. Important
aspects not covered are also worth studying, including
the costs of the regulatory system and its outcomes: are
research subjects being protected and is useful research
being promoted?Abbreviations
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